Schizophrenia and bipolar disorder are debilitating neuropsychiatric disorders, which affect 0.5-1.5% of the general population, respectively. 1 The pathogeneses of these diseases are largely unknown (for review 2, 3 ), but some studies report the hippocampus to be structurally altered in patients with schizophrenia 4 and bipolar disorder. 5, 6 A number of neurobiological theories have been proposed to explain the etiology of schizophrenia. The dopaminergic, 7 glutamatergic, 8 neurodevelopmental, 9 viral, 10 autoimmunity, 11 synaptic alterations, 12 and membrane 13, 14 theories often implicate neuropathology largely in the mesial temporal lobe. Therefore we measured two developmentally regulated proteins in the hippocampus, N-CAM and synaptophysin. N-CAM, a member of the immunoglobulin superfamily, is believed to play many roles in the development of the nervous system, including axon fasciculation, growth Increases in CSF N-CAM 100-120 kDa in patients with schizophrenia and bipolar disorder, type I were reported. 24, 25 Further, increased levels of brain N-CAM have been found in patients with schizophrenia in the cingulate cortex, hippocampus, and prefrontal cortex, 26, 27 but not in bipolar disorder patients. The N-CAM containing VASE isoform was found to be increased in the hippocampus and prefrontal cortex of bipolar patients, but not in patients with schizophrenia. 28 The SEC N-CAM isoform is produced by the incorporation of an alternative exon resulting in premature termination of transcription. 29 The possibility that the prior findings of increased N-CAM in bipolar disorder and schizophrenia 24, 25, 27, 28 were related to abnormal production of the secreted (SEC) form of N-CAM was investigated.
As an approximation of synaptic density in the hip-pocampus we measured synaptophysin, an integral membrane protein of small synaptic vesicles. 30 Although synaptophysin expression does not correlate with synaptic density or function in the case of knockout mice, 31 it is nevertheless believed to be a useful marker of change in synapse number. 32 A number of studies have shown regional changes in synaptophysin and other presynaptic proteins in the brain of patients with schizophrenia. Decreases in synaptophysin mRNA, as well as in synaptophysin protein levels, were found in several different subfields of the hippocampus in patients with schizophrenia. 33, 34 Synaptosomal-associated protein-25 kDa (SNAP-25) was decreased in the hippocampus of patients with schizophrenia, 35 while a trend for a decrease in synaptophysin was observed except in the dentate gyrus granule cells of the hippocampus. 35 Synapsin was decreased, while synaptophysin was normal, in the hippocampus of patients with schizophrenia. 36 In the prefrontal cortex, synaptophysin immunoreactivity was significantly decreased in schizophrenia. 37, 38 In the cingulate cortex of elderly patients with schizophrenia, presynaptic proteins (synaptophysin, syntaxin, and SNAP-25) were increased 39 relative to elderly controls. In general, the expression of presynaptic markers (synaptophysin, SNAP-25, and synapsin) has been found to be decreased in the hippocampus and prefrontal cortex of patients with schizophrenia.
In the present study we measured SEC N-CAM, actin, and synaptophysin in the hippocampus of four groups: controls, suicide victims, and patients with schizophrenia, or bipolar disorder. The membrane and cytosolic N-CAM (105-115 kDa) values in the hippocampus for these groups were previously measured 27 and used to calculate N-CAM (105-115 kDa)/synaptophysin ratios. Although the pathophysiology of suicide is unknown (for review 40 ), patients with mood disorders and schizophrenia are at an increased risk for suicide. 41 Therefore, as a control for the diagnostic specificity and manner of death, suicide victims were included in the assays.
Methods

Hippocampus samples
Post-mortem brains available in the Neuropathology Section of the NIMH Neuroscience Center at St Elizabeths were obtained from the Washington, DC Medical Examiners Office. Psychiatric diagnosis was assigned after chart review by two board-certified psychiatrists using DSM-III-R criteria. There were 42 samples of hippocampal tissue consisting of controls (n = 13), patients with schizophrenia (n = 16), or bipolar disorder (n = 6), and suicide victims (n = 7). There were no individuals in the suicide group for whom a definite diagnosis of unipolar or bipolar affective disorder could be established. The records indicated that four suicide victims were depressed and one individual was taking an antidepressant. Whole hippocampus samples (ෂ500 mg) were previously extracted into membrane and cytosolic fractions, 27 and protein concentrations were determined by bicinchoninic acid assay (Pierce, Rockford, IL, USA). The age, post-mortem interval, percentage of protein extracted, pH of brain, and freezer time were not different between groups (Table 1) as previously shown. 27 The membrane and cytosolic fractions of hippocampus were analyzed by Western immunoblotting for SEC N-CAM and actin, and membrane extracts were analyzed for synaptophysin.
Antibodies
An antibody to SEC N-CAM was raised against the human C-terminal sequence NH 2 -CNMFQAGLHAN-ALMK-COOH 29 by conjugation of the peptide to tetanus toxoid carrier protein by glutaraldehyde conjugation (Quality Controlled Biochemicals, Hopkinton, MA, USA). Rabbits were immunized with the peptidecarrier protein and boosted to obtain antisera against the SEC N-CAM sequence. The titer of each bleed was monitored by ELISA to the peptide and Western immunoblotting of human brain homogenate. Immune sera were affinity purified by passing through a Sepharose 4B column coupled to the SEC N-CAM peptide (Quality Controlled Biochemicals) and after washing of the column, specifically bound antisera were eluted. The C-terminal SEC peptide sequence used for immunization is unique in the Swiss Protein database, although the chicken tyrosinase precursor protein (529 amino acids) shows ෂ72% identity with the synthetic SEC N-CAM peptide immunogen; however, the human tyrosinase precursor shares only four out of 14 amino acids.
Monoclonal antibodies specific for ␤-actin, the isoform in brain tissue (Sigma clone AC-15, 1:5000 dilution) and synaptophysin (Sigma, clone SVP38) were used. The membranes were not stripped between the actin and synaptophysin incubations, since the proteins were separated sufficiently for identification, and to further preserve the amount of proteins absorbed to the nitrocellulose membrane since additional stripping and washing decreases protein retention.
A polyclonal N-CAM antibody (Becton Dickinson 3732) raised against purified human N-CAM was previously shown to immunoprecipitate N-CAM 180, 140, 120, and 105-115 kDa.
27 N-CAM 3732 was used at 1:1000 for comparison to the SEC-N-CAM immunoreactivity. A cytosolic brain extract was also immunoblotted with monoclonal N-CAM 14. 
Immunoprecipitation
The affinity purified SEC N-CAM antisera were used to immunoprecipitate brain extracts (membrane and cytosolic) using Sepharose 4B-Protein A and a slight modification of a previously published procedure 42 in which 0.05% Tween-20 was added to Buffer A 27 for washes. The SEC N-CAM immunoprecipitates were also immunoblotted with polyclonal N-CAM antisera Percentage of protein extracted from each brain sample (mg protein mg −1 weight of frozen brain tissue). F (P) is F-ratio for a one-way ANOVA and probability level.
3732. A cytosolic brain extract was immunoprecipitated with polyclonal N-CAM 3732 using the same procedure. 42 
Gel electrophoresis
The hippocampus brain samples were diluted with 2 × sample loading buffer (1 volume sample: 1 volume loading buffer, SepraSol, Integrated Separation Systems, Natick, MA, USA) and loaded in duplicate, with 60 g of total protein in one lane and 80 g in the other lane (corresponding to a total of 50-150 l). Membrane and cytosolic samples were electrophoresed on 7.5% SDS-PAGE gels for 5.5 h at 40 mA per gel. 27 The membrane and cytosolic fractions were run on separate gels, the membrane gels used control membrane occipital cortex as a reference standard (0, 20, 40, and 60 g on each gel), and for the cytosolic gels, a control cytosolic occipital cortex preparation was used as a reference standard (0, 20, 40, and 60 g on each gel). The control occipital cortex membrane and occipital cortex cytosolic preparations were prepared from the same control brain. Gels were electroblotted to Hybond C Super supported 0.45-m nitrocellulose membrane (Amersham Life Sciences, Piscataway, NJ, USA) for 30 min using a semi-dry electroblotter (Bio-Rad, Hercules, CA, USA) at 800 mAmp and 25 V constant setting.
Immunoblots
The electroblotted membrane was blocked with PBS pH 7.4, containing 1% bovine serum albumin (Sigma) and 5% non-fat powdered milk for 4-8 h at 4°C. All washes were with PBS, pH 7.4, containing 0.1% Tween 20 (PBS-T). The washing sequence consisted of PBS-T applied briefly for two rinses and followed by three PBS-T washes for 20 min on an orbital shaker. All antibodies were diluted in PBS with 0.1% bovine serum albumin and 2.5% non-fat powdered milk. The blocked membrane was washed, and incubated with primary antibody on a rocker for 16 h at 4°C, followed by washing. Secondary antibody was incubated for 40 min at room temperature on a rocker. After washing, the bound antibody complex was detected with an enhanced chemiluminescent (ECL) substrate (Amersham). The resulting light emission was col- This method for protein quantitation shows linearity between film immunodensity values and g of protein loaded using ECL reagents.
43,44
Statistical analysis
The ratio of the [(sample (immunodensity g −1 )/(reference standard (immunodensity 40 g −1 )] was calculated for each unknown sample. The 40-g standard was used to normalize all gels since for technical reasons the 60-g standard was not run on every gel. The unknown sample duplicate ratios were averaged together for the 60-g and 80-g duplicate samples. Separate one-way ANOVAs were used to evaluate differences between groups for SEC N-CAM band ratio, synaptophysin, actin, and synaptophysin/actin ratio (Statistica Version 5.1, Statsoft, Tulsa, OK, USA). The N-CAM 105-115 kDa/synaptophysin ratio was calculated using previously measured cytosolic N-CAM 105-115 kDa concentrations 27 and evaluated with a one-way ANOVA. Post hoc Tukey t-tests were calculated following significant F-ratios (level of significance ␣ Ͻ0.05). Pearson product-moment correlations were calculated between post-mortem interval and age with each of the dependent variables, ie both SEC N-CAM bands of membrane and cytosolic samples, and synaptophysin.
Results
The SEC N-CAM antisera with the strongest reactivity against the synthetic peptide CNMFQAGLHNALMK at a dilution of 1 : 800 in an ELISA, were affinity purified by passing through a column containing the synthetic CSF samples were also immunoblotted with the affinity purified SEC antibody (Figure 3a) , and no immunoreactivity was found, while strong reactivity for N-CAM 3732 is seen in CSF (Figure 3b) . The doub- The doublet band appears to represent a non-specific reaction with the secondary antibody, and does not appear when the secondary antibody is further diluted to 1: 10 000-1:20 000. 27 
Hippocampus samples
Secreted N-CAM The SEC 115 and SEC 108 bands are seen in both the hippocampus and the occipital Figure 4 ). There was no mean difference between groups in total SEC N-CAM (F (3,38) = 0.41; P = 0.74). The SEC 115/108 kDa ratios were analyzed separately for the hippocampal membrane and cytosolic extracts. In the membrane extracts of hippocampal tissue, the group main effect was significant (F(3,38) = 5.69; P = 0.002; Figure 5 ). The ratio of SEC 115/SEC 108 was increased significantly in bipolar patients (mean ± SEM; 1.50 ± 0.45) as compared to controls (0.74 ± 0.13; P = 0.03), and when bipolar patients were compared with the schizophrenia group (0.67 ± 0.07; P = 0.01). One other post-hoc comparison between groups was significant, ie suicide victims (1.35 ± 0.06) also showed a significant increase in the SEC 115/SEC 108 ratio as compared to patients with schizophrenia (P = 0.03). The same analysis was repeated with the hippocampal cytosolic samples and no significant difference was found between groups (F (3,38) = 1.92; P = 0.14).
Actin The reactivity of the actin antibody was specific for one band at 45 kDa, the expected MW (Figure 4) . The immunodensity of actin in the membrane fraction 
Figure 5
The ratio of SEC 115/SEC 108 immunodensity found in membrane extracts of hippocampus as a function of diagnosis. This ratio is increased in bipolar disorder as compared to controls (P = 0.03). The increase in bipolar disorder is also significant as compared to patients with schizophrenia (P = 0.01). Suicide victims also show an increase in the ratio of SEC 115/SEC 108 immunodensity as compared to patients with schizophrenia (P = 0.01).
was not different between groups (F (3,38) = 1.94; P = 0.13). However, in the cytosolic fraction, the ANOVA showed a significant difference between groups (F (3,38) = 6.82; P = 0.0008). The actin levels (mean ± SEM) for bipolar (0.30 ± 0.03) and suicide (0.29 ± 0.05) were significantly lower than controls (0.46 ± 0.02; P = 0.045 and P = 0.012, respectively) by post-hoc comparisons. The soluble actin levels for patients with schizophrenia (0.47 ± 0.02) were significantly increased above suicide victims (P = 0.019) while the difference between patients with schizophrenia and controls was not significant (P = 0.79).
Synaptophysin The reactivity of the synaptophysin antibody was specific for one band at 38 kDa, the expected MW (Figure 4) . Measurements of synaptophysin were possible only from the membrane fractions of the hippocampus. The cytosolic fractions did not show immunoreactivity with the synaptophysin antibody, which is consistent with the fact that synaptophysin is a membrane-bound protein. Membrane synaptophysin density was not significantly different among the groups, when all groups were compared in an ANOVA (F (3,38) = 1.21; P = 0.31).
Synaptophysin/actin ratio The concentration of synaptophysin in the membrane fraction of the hippocampus was normalized to the concentration of membranebound actin. Actin normalization is a reliable method to control for protein loading and transfer. The synaptophysin/actin ratio (Figure 6b ) was significantly different between groups (F (3,38) = 4.27; P = 0.010). There was a reduction in the membrane synaptophysin/actin ratio (ratio; mean ± SEM) for patients with schizophrenia (1.10 ± 0.12) as compared to controls (2.64 ± 0.53; P = 0.014; post-hoc comparisons corrected for unequal n and multiple comparisons). Other post-hoc group comparisons for the synaptophysin/actin ratio between controls and suicide cases (1.14 ± 0.33) or bipolar disorder (1.63 ± 0.39) were not significant. 
Cytosolic N-CAM/synaptophysin ratio
The ratio of cytosolic N-CAM 105-115 kDa/synaptophysin ( Figure  6a ) was calculated by using the previously reported data on the cytosolic N-CAM 105-115 kDa concentrations for the same samples. 27 The cytosolic N-CAM/synaptophysin ratio was significantly different between groups (F (3,36) = 4.66; P = 0.007) and was significantly increased (P = 0.017) for patients with schizophrenia (3.06 ± 0.55) as compared with controls (1.06 ± 0.28). 0.28). There was no difference between suicide (1.73 ± 0.48; P = 0.89) or bipolar disorder (0.79 ± 0.09; P = 0.99) groups as compared to controls.
Demographic variables
The correlation between pH of brain and concentrations of synaptophysin was not significant (r = −0.04). The correlations between post-mortem interval and synaptophysin (r = −0.12) and actin (r = −0.16) proteins were not significant. Age was significantly correlated with cytosolic SEC N-CAM 108 (r = 0.37, P = 0.016), but not SEC N-CAM 115. No other significant correlations between demographic and dependent variables were found.
Discussion
The SEC N-CAM 115/108 ratio for bipolar patients was increased relative to both the controls and patients with schizophrenia. No increase in the SEC N-CAM 115/108 ratio was detected for patients with schizophrenia. SEC N-CAM was not detected in CSF. Synaptophysin was decreased in patients with schizophrenia as compared to controls. The cytosolic N-CAM 105-115 kDa/synaptophysin ratio was increased in patients with schizophrenia, but not in bipolar disorder, relative to controls.
The observed differences in SEC N-CAM and synaptophysin proteins between groups were not significantly related to brain tissue pH or subject age. The pH of brain tissue, a characteristic of pre-mortem factors such as hypoxia 45, 46 was not different between groups. As was expected, post-mortem interval did not correlate with synaptophysin levels, since synaptophysin levels have previously been shown to not correlate with post-mortem intervals ranging from 36-86 h. 47, 48 Synaptophysin did not covary with membrane or cytosolic SEC 115 or SEC 108, showing that differences between these protein concentrations were independent. Long-term drug effects cannot be excluded as a possible explanation of the observed differences in the SEC N-CAM ratio between bipolar patients and controls, as well as the differences in synaptophysin between patients with schizophrenia and controls. On the other hand, a majority of bipolar patients receive neuroleptic treatment during their lifetime so it does not seem that the changes in SEC N-CAM or synaptophysin can be explained entirely by neuroleptic medication.
The bipolar patients showed a higher expression of SEC 115 than of SEC 108, whereas the control subjects showed a higher expression of SEC 108 than SEC 115.
The relationship between these two bands is not known. However, SEC 108 may be a cleaved product or metabolite of SEC 115. If this is the case, then bipolar patients may show a decreased level of metabolism or breakdown of SEC 115. The SEC N-CAM message is known to contain an alternative spliced exon, 29 and it is possible that there are two different transcripts which produce SEC 115 and SEC 108. This possibility would suggest an increased synthesis of SEC 115 relative to SEC 108 in bipolar patients. We have reported another abnormality in bipolar patients (summary in Table 2 ) involving the variable alternative spliced N-CAM exon, VASE N-CAM 145 kDa and 140 kDa. 28 Thus, different combinations of N-CAM isoforms are found in the brain of patients with schizophrenia and bipolar disorder relative to controls ( Table 2) .
Previous studies have shown increased N-CAM 105-115 kDa in patients with schizophrenia in CSF, hippocampus, and prefrontal cortex. 25, 27 It has been hypothesized that the increase in CSF N-CAM could be due to abnormal secretion of N-CAM. 24 The present study addressed the question of whether SEC N-CAM might account for the increase shown in those studies. We find that the SEC N-CAM isoform does not explain the increased N-CAM 105-115 kDa in the hippocampus. First, SEC N-CAM was not increased in patients with schizophrenia. Second, the electrophoretic mobility of cytosolic N-CAM 105-115 kDa found in CSF and brain, although fairly similar, does not match the mobility of SEC N-CAM 115 and 108 bands. Finally, there is an absence of SEC immunoreactivity in CSF while N-CAM 105-115 kDa is present. These factors suggest that increases in N-CAM 105-115 kDa in schizophrenia are not due to a change that alters the expression of SEC N-CAM. The origin of the N-CAM 105-115 kDa isoform is unknown but could be formed by cleavage of the extracellular portion of a larger 140 or 180-kDa N-CAM isoform.
In the present study we found an increase in the cytosolic N-CAM 105-115 kDa/synaptophysin ratio in the hippocampus in patients with schizophrenia. The N-CAM to synaptophysin ratio has been reported to be elevated in the cingulate cortex of schizophrenic patients, reflecting an increase in N-CAM and a concurrent decrease in synaptophysin. 26 This ratio has been suggested to be a marker of synaptic maturity 26 and synaptic remodeling. 19, 49 The origin of the cytosolic N-CAM 105-115 kDa is unknown 27 leaving the significance of the increased cytosolic N-CAM/synaptophysin ratio observed in patients with schizophrenia open to speculation. Synaptic plasticity is dependent upon functional and structural changes partially modulated by different N-CAM isoform expression. [50] [51] [52] [53] [54] [55] Patients with schizophrenia have alterations in both cytosolic N-CAM and synaptophysin in the hippocampus. It is tempting to speculate that patients with schizophrenia may have an alteration in synaptic plasticity.
Synaptophysin levels were found to be decreased in the hippocampus of patients with schizophrenia by 58% as compared to controls. This finding is consistent with prior reports showing decreased synaptophysin mRNA and protein expression in the hippocampus. 33, 34, 56 The meaning of reduced synaptophysin protein in the brains of patients with schizophrenia 33, 34, 37, 57 is unclear. Synaptophysin knock-out mice have apparently normal synapses with the exception of reductions in synaptobrevin (Ͻ20%) and quantal amplitude (Ͻ10%). 31 Mice with a knock-out of either of the synaptic proteins synapsin I or synapsin II demonstrate significant down-regulation of synaptophysin (16-27%) and synaptobrevin (16-26%), impaired synaptic transmission, and decreased synaptic vesicle density (50% reduction for double knockouts). 58 Further, reduction in synaptophysin is associated with synaptic loss and with cognitive deficits in Alzheimer's disease patients. 32, 59 Although a neurocognitive deficit has been well documented in patients with schizophrenia, 60 a distinct neuropathological hallmark of the disease process has not been described. One possibility is a reduction in synaptic vesicle density in patients with schizophrenia which would be consistent with a reduction in synaptic proteins in the hippocampus. It is tempting to speculate that the reduction in presynaptic protein expression in the hippocampus of patients with schizophrenia is related to a reduction in synaptic transmission or vesicle density. Further studies would be required to examine the effects of long term drug treatment to determine if there are alterations in other presynaptic proteins, such as synapsins and SNAP-25, and to determine whether there are overall changes in density of presynaptic vesicles. Taken together, the present findings show specific differences in protein expression in the hippocampus in two neuropsychiatric disorders: reduced presynaptic protein in patients with schizophrenia and an abnormal ratio of the neural cell adhesion molecule secreted isoforms in patients with bipolar disorder.
